Testing two new blood tests for MOGAD diagnosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study is testing two new blood tests to see if they can better diagnose MOGAD, an inflammatory condition that affects the brain and spinal cord. If you or your doctor suspects MOGAD, this trial may help confirm the diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your doctor thinks you might have MOGAD (a condition where the immune system attacks nerve coating).
- You do not have a confirmed diagnosis of AQP4-positive neuromyelitis optica spectrum disorder (a related condition) or NMDAR encephalitis (another autoimmune brain disease).
- You have not tested positive for another antibody called GFAP-IgG in your blood or spinal fluid.
- You or your guardian must agree to join the study by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene change in people with MS, NMOSD, or MOGAD to see how common it is. By joining, you help researchers learn more about these conditions and possible future treatments.
This study looks at headaches in people with MOGAD (a condition where the immune system attacks the nervous system). By understanding how common headaches are and what they feel like, doctors hope to better recognize and treat them.
This Phase 3 trial studies whether azathioprine can help prevent problems after a first attack of MOG antibody–related inflammation of the brain/spinal cord. It’s for adults with a recent first episode and confirmed MOG antibodies.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This study builds a China-based group of people with neuroinflammatory and demyelination diseases and collects health and MRI (brain scan) information. It may help doctors better understand these conditions over time and improve future treatments.
This study compares blood markers to help tell multiple sclerosis (MS) apart from a similar condition called neuromyelitis optica spectrum disorder (NMOSD). It may help find more accurate ways to diagnose these conditions.
Hear when a new Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.